Last Updated: Sunday, 26-May-2013 04:00:00 EDT
LIPTRUZET is Approved by U.S. FDA
On Friday, May 3, the U.S. FDA approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. For more information, please click here to read the announcement by Merck & Co.